260 related articles for article (PubMed ID: 29140940)
1. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.
El-Matary W; Dykes DMH; Bauman L; Elkadri A; Carroll MW; Izaguirre MR; deBruyn J; Samson CM; Crim AM; Ali S; Grossman A
Inflamm Bowel Dis; 2017 Dec; 23(12):2104-2108. PubMed ID: 29140940
[TBL] [Abstract][Full Text] [Related]
2. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.
O'Connell DM; Nachreiner J; Shu X; Terry E; Imburgia T; Vanderloo J; Lasarev MR; Bogenschutz M
J Pediatr Gastroenterol Nutr; 2022 May; 74(5):605-609. PubMed ID: 35149648
[TBL] [Abstract][Full Text] [Related]
3. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
Cheng J; Hamilton Z; Smyth M; Barker C; Israel D; Jacobson K
Inflamm Bowel Dis; 2017 Oct; 23(10):1762-1773. PubMed ID: 28837517
[TBL] [Abstract][Full Text] [Related]
5. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
[TBL] [Abstract][Full Text] [Related]
7. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
9. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
11. The extra burden of infliximab infusions in inflammatory bowel disease.
Buisson A; Seigne AL; Dʼhuart MC; Bigard MA; Peyrin-Biroulet L
Inflamm Bowel Dis; 2013 Oct; 19(11):2464-7. PubMed ID: 23942563
[TBL] [Abstract][Full Text] [Related]
12. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.
Gold SL; Cohen-Mekelburg S; Schneider Y; Shen N; Faggen A; Rupert A; Scherl EJ; Bosworth B; Steinlauf A
Inflamm Bowel Dis; 2017 Oct; 23(10):1882-1889. PubMed ID: 28837521
[TBL] [Abstract][Full Text] [Related]
13. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
14. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
[TBL] [Abstract][Full Text] [Related]
16. Infliximab in inflammatory bowel disease. Is premedication necessary?
Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
[TBL] [Abstract][Full Text] [Related]
17. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study.
Wang X; Cao J; Wang H; Ye C
Med Sci Monit; 2019 Mar; 25():2257-2264. PubMed ID: 30917108
[TBL] [Abstract][Full Text] [Related]
19. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Hammoudi N; Hassid D; Bonnet J; Tran Minh ML; Baudry C; Vauthier A; Chedouba L; Houzé P; Lourenco N; Aparicio T; Gornet JM; Allez M
Scand J Gastroenterol; 2024 May; 59(5):553-560. PubMed ID: 38353236
[TBL] [Abstract][Full Text] [Related]
20. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
